Real-world Study of CHina Ozempic cLinicAl pRactice in Patients With Type 2 Diabetes (SCHOLAR)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

34238 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-01-02

Study Completion Date

2024-03-29

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is to describe the real-world use and impact of semaglutide once-weekly (OW) among participants with type 2 diabetes mellitus (T2DM) in China. Participants diagnosed with T2DM who initiated semaglutide OW for the first time between 1 Jan 2022 (the date when semaglutide OW was listed in the National Reimbursement Drug List \[NRDL\] in China\] and 28 Feb 2023 (9 months prior to the data extraction cut-off date of 30 Nov 2023) will be included in this study. The study period will be 36 months prior to the first date of participants identification period.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Research Study Comparing a New Medicine Oral Semaglutide to Sitagliptin in People With Type 2 Diabetes

NCT04017832

Diabetes Mellitus, Type 2

COMPLETED PHASE3

Oral vs. Subcutaneous Semaglutide in Type 2 Diabetes Mellitus

NCT07056803

Diabetes Mellitus Type 2

COMPLETED

A Research Study to Compare Two Doses of Semaglutide Taken Once Weekly in People With Type 2 Diabetes

NCT03989232

Diabetes Mellitus, Type 2

COMPLETED PHASE3

A Trial Comparing Insulin Degludec/Liraglutide and Insulin Degludec in Combination With Metformin in Chinese Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Therapy and Metformin With or Without One Other Oral Antidiabetic Drug (OAD)

NCT03175120

Diabetes Diabetes Mellitus, Type 2

COMPLETED PHASE3

Research Study to Compare Three Doses of Semaglutide Tablets Taken Once Daily in People With Type 2 Diabetes

NCT04707469

Diabetes Mellitus, Type 2

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabetes Mellitus, Type 2

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Participants with T2DM

Participants diagnosed with T2DM who initiated semaglutide OW for the first time between 1 Jan 2022 (the date when semaglutide OW was listed in the National Reimbursement Drug List \[NRDL\] in China) and 28 Feb 2023 (9 months prior to the data extraction cut-off date of 30 Nov 2023.

Semaglutide

Intervention Type DRUG

Participants received semaglutide OW according to local label and to routine clinical practice at the discretion of the treating physician.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Semaglutide

Participants received semaglutide OW according to local label and to routine clinical practice at the discretion of the treating physician.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Ozempic

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or female participants aged greater than or equal to (≥) 18 years on index date
* Participants with diagnosis of T2DM prior to or on index date
* Participants with initiation of semaglutide OW for the first time within the identification period

Exclusion Criteria

* Participants with diagnosis of type 1 diabetes prior to or on index date
* Participants who were pregnant within 36 months prior to or on index date
* Participants who participated in any clinical trials within 36 months prior to or on index date which could be identified from medical records

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No